10 October 2017 – CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, has entered into a definitive agreement to acquire JOTEC AG for an upfront payment of US$ 225 million, subject to certain adjustments. JOTEC is a German-based, privately-held leading developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair. The transaction is expected to close later this year, subject to customary closing conditions.

Walder Wyss AG acted as lead counsel to the private sellers. The team has been co-led by Markus Vischer (Partner, Corporate/M&A) and Urs Gnos (Partner, Corporate/M&A) and further included Boris Räber (Associate, Corporate/M&A), Claudia Weber (Associate, Corporate/M&A), Vera Krüttli (Associate, Corporate/M&A), Michael Kündig (Associate, Corporate/M&A), Mirjam Olah (Associate, Corporate/M&A), Nico Bernhard (Associate, Corporate/M&A), Lukas Wyss (Partner, Banking & Finance), Tervel Stoyanov (Associate, Banking & Finance), Martin Busenhart (Partner, Tax), Janine Corti (Counsel, Tax), Reto Jacobs (Partner, IP&IT) Gion Giger (Managing Associate, IP&IT), Ewa Szczogiel (Junior Associate, Corporate/M&A) and Dominik Wingeier (Trainee, Corporate/M&A).